Sun Pharma research unit licenses epilepsy drug Elepsia XR to parent

India’s Sun Pharma Advanced Research Company (SPARC) has licensed its novel epilepsy drug Elepsia XR (levetiracetam) to its parent, Mumbai-based Sun Pharmaceutical Industries, as a way to speed up U.S. market entry following manufacturing issues that prevented a launch last year.

Under the terms of the deal, SPARC gets $10 million in an upfront payment as well as milestone and royalty payments linked to sales.

SPARC had received approval for the drug from the U.S. FDA in March 2015 and at the time said it was evaluating partners for commercial sales that were initially forecast at about $50 million annually.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

However, the manufacture of the product at the Halol plant owned by the parent was delayed because of manufacturing violations cited by the U.S. FDA.

In a release, Sun said it is at work on bringing the Halol site up to compliance and suggested the licensing deal will aid the introduction of Elepsia into the market without providing details.

“The in-licensing of ELEPSIA XR will facilitate Sun Pharma’s anticipated entry into the proprietary CNS segment in the U.S.," Kirti Ganorkar, senior vice president for Business Development at the parent said in a statement.

"This is a part of Sun Pharma’s strategy, to strengthen its presence in the US specialty segment through its newly created Sun Neurosciences business unit."

Last year, Reuters had reported that the company had worked "very aggressively" to find partners for the product and was in "some advanced discussions" to launch by the second half of fiscal 2016.

- here's the website

Related Article:
India's Sun Pharma research arm sees FDA nod for Elepsia XR yanked by FDA on manufacturing

Read more on

Suggested Articles

A buyer could emerge from private equity funds, European pharma players and Indian or Asian drugmakers looking to expand in Europe.

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

Hanmi loses Janssen obesity pact, while Yuhan signs NASH deal with Boehringer. GSK sells a Chinese site to Fosun as it opens facilities in Singapore.